Is it Time to Reconsider and Re-Stratergise B Lymphocyte Based Immunotherapy?

Abstract

The present scenario of pandemic era has witnessed milestone development in the field of immunotherapeutic and vaccine engineering. It has evoked a breech in the routine therapeutic strategies that was conventionally followed. The new outlook in the immunological aspect of major diseases as helped to refocus back on to the basic immune responses associated with innate response against disease prevention and progression. The current trend to re-strategize the treatment options for patients suffering from cancer in the light of immunotherapy has gained its importance. Recently, immune-therapeutic has gained a great interest in treatment of Oral Squamous Cell Carcinoma (OSCC). The Tcell based immune targeted approach of T-cell based therapy, CAR-T (chimeric antigen receptor) and its success has nailed its best attempt in immunotherapy of Head and Neck Cancer (HNSCC) [1,2]. However, the role of humoral response against the tumor especially of B lymphocytes has not gained its due importance for many reasons. The present situation on the other hand is more encouraging to attempt and utilize the vast potentiality of the B lymphocyte especially the antigen and antibody associated immune response.